| خلاصه مقاله | Among the various forms of liver cancer diagnosed in 2020, hepatocellular carcinoma
(HCC) took the lead, constituting approximately 75-85% out of the nearly 906,000 reported cases.
Additionally, HCC ranked as the third highest cause of cancer-related deaths globally in 2020, with an
estimated 5-year survival rate of 20%. The primary aim of this study is to ascertain novel biomarkers
associated with HCC, enabling the prediction of prognosis and the advancement of treatment
strategies [1,2].
Methods: The GSE101685 dataset was obtained from GEO database, consisting of 24 cancer and 8
normal samples. To assess the consistency of the samples, Principal Component Analysis (PCA) was
carried out. Subsequently, the statistical analysis was performed utilizing the LIMMA package.
Differential expression of genes (DEGs) was determined based on the criteria of | 𝑙𝑙𝑙𝑙𝑙𝑙 2 𝐹𝐹𝐹𝐹 |> 3 and adj
P-value < 0.05. To examine the relationship between gene expression and survival outcomes, the
Kaplan-Meier plotter was utilized.
Results: Microarray analysis was conducted to assess the expression profile of 69 samples. A total of
126 DEGs were identified, of which 43 were up-regulated and 83 were down-regulated. Among them,
two genes SLCO1B3, and CLEC4M have been discovered in previous studies to be related to cancers
such as Prostate and lung. These two genes show a significant decrease in expression in this dataset.
Through the utilization of the GeneCards and Reactome pathway databases, it has been determined
that these genes possess the ability to regulate significant pathways, including Bile acid and bile salt
metabolism and Complement cascade. According to Kaplan-Meier plots DEGs are correlated with
poor prognosis in HCC.
Conclusion: Our examination reveals that the SLCO1B3 and CLEC4M genes are vital in HCC and
strongly associated with poor prognosis. |